# US 6,730,304 B2 · Variant of LAV viruses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,304 B2
- Document ID: US6730304B2
- Status: Granted
- Kind: B2
- Application number: 10/017,580
- Filed: 2001-12-18
- Published: 2002-11-14
- Granted: 2004-05-04
- Earliest claimed: 1986-06-23
- Assignees: Institut Pasteur
- Inventors: Marc Alizon; Pierre Sonigo; Simon Wain-Hobson; Luc Montagnier
- Web page: https://patentgrep.com/patent/US6730304B2

## CPC

- C12Q 1/702: {for retroviruses}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12Q 1/703: {Viruses associated with AIDS}
- G01N 33/56988: {HIV or HTLV}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2740/16021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2740/16051: Methods of production or purification of viral material
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A variant of a LAV virus, designated LAVMAL and capable of causing AIDS. The cDNA and antigens of the LAVMAL virus can be used for the diagnosis of AIDS and pre-AIDS.

## Claims

### Claim 1

A polypeptide fragment, wherein said polypeptide fragment binds to antibodies in LAS patient sera, and wherein said polypeptide fragment comprises an HIV-1MAL epitope that does not react with antibodies directed against specific epitopes of HIV-1 IIIB, HIV-1BRU, HIV-1ARV-2, or HIV-1ELI.

### Claim 2 (depends on 1)

The polypeptide fragment of claim 1, wherein said polypeptide fragment comprises 5-150 amino acid residues.

### Claim 3 (depends on 1)

An immunogenic composition comprising the polypeptide fragment of claim 1.

### Claim 4 (depends on 2)

An immunogenic composition comprising the polypeptide fragment of claim 2.

### Claim 5

A polypeptide fragment, wherein said polypeptide fragment binds to antibodies in LAS patient sera, and wherein said polypeptide fragment comprises an HIV-1MAL epitope that does not react with antibodies directed against specific epitopes of HIV-1IIIB, HLV-1BRU, or HIV-1ARV-2.

### Claim 6 (depends on 5)

The polypeptide fragment of claim 5, wherein said polypeptide fragment comprises 5-150 amino acid residues.

### Claim 7 (depends on 5)

An immunogenic composition comprising the polypeptide fragment of claim 5.

### Claim 8 (depends on 6)

An immunogenic composition comprising the polypeptide fragment of claim 6.
